Hyloris Pharmaceuticals SA: Hyloris reports results for the full year 2021

Added 4 additional innovative product candidates Strong growth in H2 leading to total revenues of €3.1 million (€0.2 million in 2020) Significant expansion of commercial footprint of Maxigesic

Related Keywords

Belgium ,Norway ,Malaysia ,Australia ,United Kingdom ,Luxembourg ,Austria ,Canada ,Woman ,Bahrain ,Pakistan ,Germany ,Mexico ,Iceland ,Thailand ,New Zealand ,Denmark ,Netherlands ,Israel ,Albania ,Italy ,Ireland ,South Korea ,Panama ,France ,Spain ,Cyprus ,Greece ,Belgian ,Thomas Jacobsen ,Vaneltix Pharma ,Vulvovaginal Candidiasis ,Olivier Declercq ,Abid Irshad ,Jean Luc Vandebroek ,Stijn Van Rompay ,Chris Buyse ,Delveinsight Market Research ,Alter Pharma Group ,Department Of Radiology ,University Of South Carolina College Medicine ,Linkedin ,Hyloris Pharmaceuticals ,Leukemia Lymphoma Society ,Academic Pharmaceuticals ,Hyloris Pharmaceuticals Sa Euronext Brussels ,Business Development ,Euronext Brussels ,Chief Executive Officer ,Delveinsight Market ,Domiphen Bromide ,Purna Female Healthcare ,Recurrent Vulvovaginal Candidiasis ,Pleco Therapeutics ,Healthcare April ,Lymphoma Society ,Medical University ,South Carolina College ,Fusidic Acid Cream ,Fusidic Acid ,Chief Business Development Officer ,Chief Financial Officer ,Managing Director ,Initial Public ,Hyloris ,Pharmaceuticals ,Reports ,Results ,Bull ,Ear ,021 ,